Sleep Disorders in Parkinson Disease

2011 ◽  
Vol 17 ◽  
pp. S38-S42 ◽  
Author(s):  
Alex Iranzo de Riquer ◽  
Alberto Bergareche ◽  
Victor Campos
2015 ◽  
Vol 16 ◽  
pp. S349
Author(s):  
M. Ruthranesan ◽  
A. Am

Author(s):  
Elisaveta Sokolov ◽  
K. Ray Chaudhuri

Disturbances in nocturnal sleep and their consequences during waking in Parkinson disease (PD) were recognized in 1817 by James Parkinson, who described sleep problems in his case series as follows: “His attendants observed, that of late the trembling would sometimes begin in his sleep, and increase until it awakened him: when he always was in a state of agitation and alarm.” Sleep disturbance in PD is complex, with a prevalence of up to 98%, and has been shown to be a key determinant of quality of life. Sleep disturbances in PD are heterogeneous, ranging from insomnia to drug-induced sleep disorders, and now can be assessed by simple validated bedside tools such as the Parkinson’s Disease Sleep Scale (PDSS). Also, sleep, contrary to previous perceptions, can be disordered not just in advanced PD, but also in the pre-motor as well as the untreated states.


2013 ◽  
Vol 09 (11) ◽  
pp. 1119-1129 ◽  
Author(s):  
Ariel B. Neikrug ◽  
Jeanne E. Maglione ◽  
Lianqi Liu ◽  
Loki Natarajan ◽  
Julie A. Avanzino ◽  
...  

Author(s):  
Castejón OJ ◽  
◽  
Carrero-González Carmen Maria ◽  

We have observed semantic memory and episodic memory disorders (100%) in patients ranging from 40 to 92 years-old, associated to cardiovascular diseases and blood hypertension (82%), sleep disorders (50%), neurobehavioral disorders (44%), such as depression, anxiety, aggression, and vascular demencia, disorders of language (36%), neurosensory disorders (28%), as diminution of visual and hearing acuity, dizziness (26%), Parkinson disease (34%), Alzheimer disease (21%), gait disturbances (10%), vertigo (10%), cervicalgia and cervicogenic headache (10%) trigeminal neuralgia (2%,), We observed as comorbidities the following non-nervous diseases: metabolic diseases as diabetes (21%) and hypothyroidism (5%), gastrointestinal pathology (21%), such as constipation, loss of sphincter control, and gastritis, arthritis (13%), prostatic hypertrophy (1%) and loss of weight (1%). We consider that according to their high frequency the most risk factors associated to memory disorders are cardiovascular diseases and blood hypertension (82%), sleep disorders (50%), neurobehavioral disorders (44%), such as depression, anxiety, aggression, and vascular demencia, disorders of language (36%), neurosensory disorders (28%), as diminution of visual and hearing acuity, dizziness (26%), and Parkinson disease (34%).


2018 ◽  
Vol 41 ◽  
pp. 101-112 ◽  
Author(s):  
Ziv Gan-Or ◽  
Roy N. Alcalay ◽  
Guy A. Rouleau ◽  
Ronald B. Postuma

2021 ◽  
Vol 3 (2) ◽  
pp. 1-9
Author(s):  
Carrero-González Carmen Maria ◽  
◽  
Castejón OJ ◽  
Judith Cristina Martínez Royert ◽  
◽  
...  

We have observed semantic memory and episodic memory disorders (100%) in patients ranging from 40 to 92 years-old, associated to cardiovascular diseases and blood hypertension (82%), sleep disorders (50%), neurobehavioral disorders (44%), such as depression, anxiety, aggression, and vascular demencia, disorders of language (36%), neurosensory disorders (28%), as diminution of visual and hearing acuity, dizziness (26%), Parkinson disease (34%), Alzheimer disease (21%), gait disturbances (10%), vertigo (10%), cervicalgia and cervicogenic headache (10%) trigeminal neuralgia (2%,), We observed as comorbidities the following non-nervous diseases: metabolic diseases as diabetes (21%) and hypothyroidism (5%), gastrointestinal pathology (21%), such as constipation, loss of sphincter control, and gastritis, arthritis (13%), prostatic hypertrophy (1%) and loss of weight (1%). We consider that according to their high frequency the most risk factors associated to memory disorders are cardiovascular diseases and blood hypertension (82%), sleep disorders (50%), neurobehavioral disorders (44%), such as depression, anxiety, aggression, and vascular demencia, disorders of language (36%), neurosensory disorders (28%), as diminution of visual and hearing acuity, dizziness (26%), and Parkinson disease (34%).


CHEST Journal ◽  
2020 ◽  
Author(s):  
Annie C. Lajoie ◽  
Anne-Louise Lafontaine ◽  
Marta Kaminska

Sign in / Sign up

Export Citation Format

Share Document